Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of adjunctive cannabidiol for rare disease-associated severe epilepsy in children and young adults
2023-503709-12-00Phase 2Authorised
- Sponsor
- Meyer Children's Hospital IRCCS
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in epilepsy, sponsored by Meyer Children's Hospital IRCCS. Primary endpoints: Percentage change in motor seizure frequency and EEG improvement score. Planned start Jun 2023; status: authorised.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2023-503709-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503709-12-00.